Evidence map›Paper›PMID 36059109›Full record

SynthesisEuropean psychiatry : the journal of the Association of European Psychiatrists2022

European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Antonio Vita, Wolfgang Gaebel, Armida Mucci, Gabriele Sachs, Andreas Erfurth, Stefano Barlati, Federico Zanca, Giulia Maria Giordano, Louise Birkedal Glenthøj, Merete Nordentoft and 1 more

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in European psychiatry : the journal of the Association of European Psychiatrists, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07759895 (Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia), which is not on this map. Cited by 64 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 5 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07759895 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia

TypeinterventionalSponsorAmit LotanRan2026 to 2029Enrolled80ConditionsSchizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative SymptomsArmsDeferiprone (DFP), N-Acetyl Cysteine (NAC)
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Understanding the burden of cognitive impairment associated with schizophrenia: Results from the international LUCIA study.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Electroconvulsive therapy and autobiographical memory.Psychiatry, psychology, and law : an interdisciplinary journal of the Australian and New Zealand Association of Psychiatry, Psychology and Law · 2026
    Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Antonio VitaDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Wolfgang GaebelWHO Collaborating Centre on Quality Assurance and Empowerment in Mental Health DEU-131, LVR-Klinikum Düsseldorf, Düsseldorf, Germany.
Armida MucciUniversity of Campania "Luigi Vanvitelli", Naples, Italy.ORCID 0000-0002-6195-9456
Gabriele SachsMedical University of Vienna, Wien, Austria.ORCID 0000-0002-8359-9877
Andreas ErfurthMedical University of Vienna, Wien, Austria.ORCID 0000-0003-3870-3521
Stefano BarlatiDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0002-1784-3915
Federico ZancaUniversity of Campania "Luigi Vanvitelli", Naples, Italy.
Giulia Maria GiordanoUniversity of Campania "Luigi Vanvitelli", Naples, Italy.
Louise Birkedal GlenthøjCORE - Copenhagen Research Centre for Mental Health, Copenhagen University Hospital, Copenhagen, Denmark.
Merete NordentoftCORE - Copenhagen Research Centre for Mental Health, Copenhagen University Hospital, Copenhagen, Denmark.
Silvana GalderisiUniversity of Campania "Luigi Vanvitelli", Naples, Italy.ORCID 0000-0002-1592-7656
University of Campania "Luigi Vanvitelli" · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITMedical University of Vienna · ATCopenhagen University Hospital · DKEuro-Centrum · PLUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImpairment in a wide range of cognitive abilities has been consistently reported in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are thought to underlie severe functional disabilities associated with schizophrenia. Despite the key role in schizophrenia outcome, cognition is still poorly assessed in both research and clinical settings.

methodsIn this guidance paper, we provide a systematic review of the scientific literature and elaborate several recommendations for the assessment of cognitive functions in schizophrenia both in research settings and in real-world clinical practice.

resultsExpert consensus and systematic reviews provided guidance for the optimal assessment of cognitive functions in schizophrenia. Based on the reviewed evidence, we recommend a comprehensive and systematic assessment of neurocognitive and social cognitive domains in schizophrenia, in all phases of the disorder, as well as in subjects at risk to develop psychosis. This European Psychiatric Association guidance recommends not only the use of observer reports but also self-reports and interview-based cognitive assessment tools. The guidance also provides a systematic review of the state of the art of assessment in the first episode of psychosis patients and in individuals at risk for psychosis.

conclusionThe comprehensive review of the evidence and the recommendations might contribute to advance the field, allowing a better cognitive assessment, and avoiding overlaps with other psychopathological dimensions. The dissemination of this guidance paper may promote the development of shared guidelines concerning the assessment of cognitive functions in schizophrenia, with the purpose to improve the quality of care and to obtain recovery.

Indexed as

Cognition DisordersCognitive DysfunctionPsychotic DisordersSchizophreniaHumansNeuropsychological TestsSchizophrenic PsychologyAssessment instrumentscognitive functioningevidence-basedpsychosocial functioningsystematic review

Identifiers

PMID36059109
PMCPMC9532219
OpenAlexW4294628117

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.